Get latest articles and stories on Latest News at LatestLY. Aurobindo Pharma on Saturday said its consolidated net profit increased 10 per cent to Rs 571 crore in the first quarter ended June 30, 2023, on account of robust sales across regions. Latest News | Aurobindo Pharma Q1 Profit Up 10 Pc at Rs 571 Cr.
With the product pipeline continuing to advance, and execution of growth drivers proceeding as planned, the company is confident that its fundamental strengths position it to create an upward trajectory, Vice-Chairman and Managing Director K Nithyananda Reddy said.
The sub-licensing agreement for Nilotinib capsules, originally developed by Novartis, will be in 44 low and middle-income countries (LMIC), including the seven countries where patents on the product are pending or in force, Aurobindo Pharma said in a regulatory filing.
Aurobindo Pharma on Friday said its wholly-owned arm, Eugia Pharma Specialities Ltd has entered into a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market an anti-cancer drug.
India s Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia.